Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Velcade with melphalan-prednisone, cyclophosphamide-prednisone, or prednisone alone in newly diagnosed elderly multiple myeloma
2010-018873-39Phase 2Completed
- Sponsor
- HOVON
- Start
- Jul 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM) (3 arms), sponsored by HOVON. Primary endpoints: Very good partial response rate, Complete response rate and 1 more. Started Jul 2010; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-018873-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018873-39.